Eveo Cell Therapy Platform Launched by Sartorius to Address Structural Manufacturing Bottlenecks

Sartorius’ life science group is launching an integrated system for the production and quality control (QC) of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to treatments such as CAR T therapies, according to the company.

“Cell therapies are redefining medical possibilities. Yet, they remain accessible to only a small share of patients because manufacturing is complex, capacity-constrained, and therefore expensive. With our integrated platform, we are tackling these structural bottlenecks head-on,” said René Fáber, member of the executive board at Sartorius.

“By combining raw materials, production equipment, software and QC assays into a scalable system, we enable our customers to expand output, significantly reduce cost per dose, and shorten vein-to-vein time for patients.”

Conventional manufacturing models for autologous cell therapies rely on centralized, purpose-built facilities, that require significant greenfield investment, staff recruitment, training and multi-year build-up phases, continued Fáber, adding that, nevertheless, around 60 percent of regulatory disruptions in cell therapy production are caused by manufacturing and process-related issues.

The Eveo platform addresses these challenges by integrating cell selection, activation, gene modification, expansion, wash and concentration and final formulation into a closed system, using a variety of Sartorius solutions from critical raw materials to bioreactors and separation technologies, noted a company spokesperson. The system’s compact design supports implementation in existing facilities with existing staff, allows for operation in lower-classification environments and supports centralized and decentralized manufacturing models, explained the Sartorius official.

Sartorius has collaborated with ElevateBio, a cell therapy CDMO, among other partners, to test the Eveo platform. In a pilot study, the system reportedly performed in line with design expectations, demonstrating its real-world applicability.

Due to its multi-parallel configuration, a single operator can process eight patient batches at once in the same cleanroom space traditionally needed for two batches, according to Sartorius. Assuming a manufacturing time of around seven days per batch and 50 production weeks per year, Eveo enables production of more than 350 doses per year in a footprint that today yields roughly 100 doses, an almost fourfold increase, pointed out the spokesperson.

Sartorius plans to begin taking orders for the new product in September, with first deliveries expected in 2027. ElevateBio is a preferred partner and will be granted access to one of the first Eveo platforms for use with its manufacturing customers.